O, 24.79 BPC-157 (Body Protection Compound-157) is a bioactive pentadecapeptide that exerts its effects through multiple complementary mechanisms, primarily involving modulation of the nitric oxide (NO) signaling pathway, upregulation of angiogenic factors such as VEGF, and activation of key cell survival and repair pathways including FAKpaxillin and MAPK signaling
On April 30, 2026, FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list
FDA-Approved Branded Medications: These are finished products that have undergone FDA review for safety, efficacy, and manufacturing quality
Compounded medications aren't FDA-approved in the same way as branded drugs, and the quality can vary depending on the compounding pharmacy
WikiPathways: connecting communities